AlphaMadera's AlphaVal page computes Novo Nordisk A/S's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag NVO as undervalued, fairly valued, or overvalued.

What is Novo Nordisk A/S's fair value?

Fair value for NVO is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value NVO?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from NVO's most recent reported fundamentals.

NVO - Novo Nordisk A/S

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $47.00 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

High-Growth Software 80% confidence

Primary model: Revenue × Terminal Margin DCF

Valuation Signal Overvalued Moderate

Trading 24.8% above fair value

Current Price $44.96

Bear Case $28.98 35.5% downside ($28.98 - $44.96) / $44.96 = -35.5% 8% rev growth, 21% terminal margin

Fair Value $36.02 19.9% downside ($36.02 - $44.96) / $44.96 = -19.9% 7% rev growth, 28% terminal margin

Bull Case $47.22 5.0% upside ($47.22 - $44.96) / $44.96 = 5.0% 9% rev growth, 32% terminal margin

Adjust Assumptions

Revenue Growth Rate

7.0%

Terminal FCF Margin

28.0%

Discount Rate

12.0%

Key Value Driver

Revenue growth (7%) × margin expansion to 28%

Terminal Value % of EV 57%

Implied Market Multiple 4.5x

Plain-Language Summary

Our base-case estimate uses a discounted cash flow model based on revenue growth and long-run free cash flow margins. We then blend that result with the average analyst price target of $47.00 from 39 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $36.02 per share.

Warnings

⚠ Our estimate assumes profit margins grow from 9% to 28% over 10 years. If that improvement stalls, the company is worth considerably less.

ℹ Gross margin of 81% means each dollar of revenue is highly profitable. As the company grows, overhead costs should shrink as a share of revenue, boosting overall profits.

ℹ Wall Street's average price target is $47.00 (from 39 analysts). Our estimate is 33% below the consensus -- consider that gap carefully.

ℹ Financial statements were converted from DKK into USD using USDDKK at 0.1556 USD per DKK.

Key Risks

Current FCF misleads — the model values future margins, not today's cash
SBC dilution is the hidden tax: 2-4% annual share growth compounds fast
Revenue deceleration is inevitable — the question is when and how steep